Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
Follow ORGS
Orgenesis Inc. (ORGS) Piotroski F-score
Orgenesis Inc.'s Piotroski F-score for fiscal 2024 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, up from 1 in fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 3 | 2.00 |
| FY2023 | 1 | (2.00) |
| FY2022 | 3 | 0.00 |
| FY2021 | 3 | (2.00) |
| FY2020 | 5 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (605.73%) | (104.97%) | Fail | 0 |
| Positive operating cash flow | (17.08m) | (14.84m) | Fail | 0 |
| Rising return on assets | (605.73%) | (104.97%) | Fail | 0 |
| Cash flow above net income | 31.09m | 40.52m | Pass | 1 |
| Falling long-term leverage | 1.07 | 0.36 | Fail | 0 |
| Rising current ratio | 0.03 | 0.25 | Fail | 0 |
| No new shares issued | 4,210,800 | 2,900,800 | Fail | 0 |
| Rising gross margin | (86.28%) | (1,080.19%) | Pass | 1 |
| Rising asset turnover | 0.13 | 0.01 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | 4 |
| BGMS Bio Green Med Solution, Inc. compare | 4 |
| TRAW Traws Pharma, Inc. compare | 4 |
| ORGS Orgenesis Inc. | 3 |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 3 |
| IMNN Imunon, Inc. compare | 2 |
| CANF Can-Fite Biopharma Ltd compare | 2 |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover